eyonis LCS
Phase 3- Indications
- Lung cancer screening
Company intelligence / Profile preview
Median Technologies is a leading provider of advanced medical imaging solutions for oncology clinical trials and patient care. Their proprietary AI-driven platforms enable earlier cancer diagnosis, improved monitoring, and more precise assessment of treatment response. The company's iCRO service is widely used by global biopharma companies in all phases of drug development. Their eyonis™ suite aims to disrupt early detection in serious diseases like lung and liver cancer using AI/ML-based software as medical devices
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Median Technologies.